Check out our comprehensive educational activities here

What is the definition of elderly in AML, and is there an age at which we decide not to treat?

Join Dr. Nazha as he defines elderly AML, discusses whether or not age should be a factor in deciding whether to treat a patient, and describes recommended treatments for patients of varying ages.

Published on October 9, 2017 in Treatment

CPX-351 and Vosaroxin: Developments in Chemotherapy for AML

In this interview, AML thought-leaders Dr. Jorge Cortes and Dr. Farhad Ravandi provide insight on recent and ongoing clinical trials studying CPX-351 and vosaroxin.

Published on September 29, 2017 in Treatment in Clinical Trials

What are the contributing factors to poor outcomes in older patients with AML?

Join Dr. Nazha as he discusses the factors that contribute to poor outcomes in older patients with AML.

Published on September 26, 2017 in Treatment

Enasidenib in mutant-IDH2 R/R AML: Results of a phase 1 dose-escalation and expansion study

Dr. Eytan Stein provides a brief update on phase 1 arms of a trial studying the effectiveness of enasidenib in patients with relapsed and refractory AML and an IDH2 mutation.

Published on August 21, 2017 in Treatment

CPX versus 7 and 3 conventional chemotherapy in older adults with AML

Dr. Stuart Goldberg briefly summarizes updates on CPX-351, a liposomal form of cytarabine and daunorubicin that allows for office infusion vs. standard consolidation requiring hospitalization.

Published on August 7, 2017 in Treatment

Differentiation syndrome associated with enasidenib, a selective inhibitor of mutant IDH2

Dr. Eytan Stein provides a brief update on patients experiencing differentiation syndrome in a larger enasidenib trial, detailing the creation of a Differentiation Syndrome Review Committee.

Published on July 31, 2017 in Treatment

Should all fit, newly diagnosed patients with AML receive 3+7 based induction therapy?

Join Dr. Stone as he explains which patients will benefit the most from 3+7 therapy.

Published on July 24, 2017 in Treatment

How should patients with relapsed mutant FLT3 AML be treated?

In this activity, Dr. Stone will discuss how the midostaurin can be used in the upfront setting for patients with mutant FLT3 AML.

Published on July 17, 2017 in Treatment

What is the emerging role of FLT3 inhibitors in the treatment of newly diagnosed AML?

Join Dr. Stone as he discusses the approval of midostaurin for acute myeloid leukemia, including its use in combination.

Published on July 10, 2017 in Treatment

What are the most exciting new agents in AML and where are they in clinical development?

Dr. Naval Daver discusses the most exciting new agents in acute myeloid leukemia, including their current status in clinical development.

Published on May 31, 2017 in Treatment